The massive success of blockchain technology in Bitcoin is taking the world by storm by attracting vast acceptance from both the public and private sectors. Blockchain allows digital transactions between two parties without a third party as a broker. Blockchain is now applicable beyond fintech to various other industries. Among these, Hyperledger fabric has emerged as the most popular blockchain-based open-source permissioned platform targeting business applications. It has been used in over 400 proofs-of-concept blockchain and is well proven in applications, such as supply chain, healthcare, and so on. Despite the many obvious benefits observed in blockchain-enhanced platforms, there still exist technical challenges in scalability, causing performance deficiency, which includes latency and throughput. There is an exigent need to improve the current blockchain-based applications to have the blockchain nodes be scalable without compromising the blockchain performance. In this study, we present the impact of workload variance of up to 1000 transactions with the setup of 20 blockchain nodes in the Hyperledger LTS platform. The evaluation metrics are transaction success and failure rate, throughput, and latency in the blockchain. The transaction throughput was found to be consistent with the increasing workload on a constant number of nodes. However, it showed a declining trend with an increasing number of nodes. As far as the latency, it was in tandem with the increased workload and the number of nodes. We, therefore, conclude that the LTS version is suitable for small and medium enterprises that do not scale up.
A phytochemical investigation on the ethyl acetate soluble fraction of Lonicera quinquelocularis (whole plant) led to the first time isolation of one new phthalate; bis(7-acetoxy-2-ethyl-5-methylheptyl) phthalate (3) and two new benzoates; neopentyl-4-ethoxy-3, 5-bis (3-methyl-2-butenyl benzoate (4) and neopentyl-4-hydroxy-3, 5-bis (3-methyl-2-butenyl benzoate (5) along with two known compounds bis (2-ethylhexyl phthalate (1) and dioctyl phthalate (2). Their structures were established on the basis of spectroscopic analysis and by comparison with available data in the literature. All the compounds (1-5) were tested for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities in dose dependent manner. The IC50 (50% inhibitory effect) values of compounds 3 and 5 against AChE were 1.65 and 3.43 µM while the values obtained against BChE were 5.98 and 9.84 µM respectively. Compounds 2 and 4 showed weak inhibition profile.
The outbreak of COVID-19 has caused great havoc and affected many parts of the world. It has imposed a great challenge to the medical and health fraternity with its ability to continue mutating and increasing the transmission rate. Some challenges include the availability of current knowledge of active drugs against the virus, mode of delivery of the medicaments, its diagnosis, which are relatively limited and do not suffice for further prognosis. One recently developed drug delivery system called nanoparticles is currently being utilized in combating COVID-19. This article highlights the existing methods for diagnosis of COVID-19 such as computed tomography scan, reverse transcription-polymerase chain reaction, nucleic acid sequencing, immunoassay, point-of-care test, detection from breath, nanotechnology-based bio-sensors, viral antigen detection, microfluidic device, magnetic nanosensor, magnetic resonance platform and internet-of-things biosensors. The latest detection strategy based on nanotechnology, biosensor, is said to produce satisfactory results in recognizing SARS-CoV-2 virus. It also highlights the successes in the research and development of COVID-19 treatments and vaccines that are already in use. In addition, there are a number of nanovaccines and nanomedicines currently in clinical trials that have the potential to target COVID-19.